Counseling Your Patients on the Risk of Shingles

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Counseling Your Patients on the Risk of Shingles



ReachMD Healthcare Image

How do we talk to our patients 50 years and older about their risk of shingles?

Sponsored by GSK

  • Sponsored by

  • Overview

    Shingles can impact many of our patients 50 years and older, which is why we need to talk to them about their risk. To take a look at counselling strategies, Dr. Jennifer Caudle is joined by Dr. Christopher Altman, Director of Immunization & Clinical Programs.

    Sponsored by GSK


    SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

    SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).


    • SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
    • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
    • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
    • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
    • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
    • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
    • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
    • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
    • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

    Please see full Prescribing Information for SHINGRIX.

    Trademarks are property of their respective owners.

    ©2022 GSK or licensor.
    SGXWCNT220051 December 2022
    Produced in USA.

Schedule23 Sep 2023